Download PDF
Zeitschrift für Orthomolekulare Medizin 2024; 22(02): 10-13
DOI: 10.1055/a-2311-8013
Wissen

Trojanische Pferde in der Onkologie

Antikörper-Wirkstoff-Konjugate ergänzen das Arsenal der zielgerichteten Therapieoptionen
Peter Holzhauer
,
Frederik Götte
› Further Information
    Permissions and Reprints

Zusammenfassung

Antikörper-Wirkstoff-Konjugate (ADC) sind eine neue Medikamentenklassen mit zytotoxischer Wirkung. Sie ergänzen das Angebotsspektrum der onkologischen Therapieoptionen. Neuere ADC haben eine höhere Effektivität, die jedoch auch eine höhere Toxizität bedeuten kann. In dem Beitrag stellen die Autoren einzelne ADC mit ihren zugelassenen Behandlungsoptionen vor.

Schlüsselwörter

Antikörper-Wirkstoff-Konjugate - ADC - Onkologie - Linker - Antikörper - Zytostatika


Publication History

Article published online:
17 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Willen C. Antikörper-Wirkstoff-Konjugate der 3. Generation: Breite Wirkung im Tumor. Dtsch Arztebl 2022; 119: 31-32 A-1356/B-1138
    Google Scholar
  • 2 Food and Drug Administration. Approval Letter brentuximab vedotin. August 19, 2011
  • 3 Chatterjee S. et al. Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy. Eur J Pharmacol 2021; 911: 174516 DOI: 10.1016/j.ejphar.2021.174516.
    CrossrefPubMedGoogle Scholar
  • 4 Chu PG. et al. CD79: a review. Appl Immunohistochem Mol Morphol 2001; 9: 97-106 DOI: 10.1097/00129039-200106000-00001.
    CrossrefPubMedGoogle Scholar
  • 5 European Medicines Agency, Adcetris. EPAR – Product information. First published 22/11/2012, Last updated 01/12/2023
  • 6 European Medicines Agency, Besponsa. EPAR – Product Information. First published 13/07/2017, Last updated 14/02/2024
  • 7 European Medicines Agency, Enhertu. EPAR – Product information. First published 08/02/2021, Last updated 05/03/2024
  • 8 European Medicines Agency, Kadcyla. EPAR – Product Information. First published 19/12/2013, Last updated 22/03/2023
  • 9 European Medicines Agency, Mylotarg. EPAR – Product Information. First published: 04/05/2018, Last updated: 20/11/2023
  • 10 European Medicines Agency, Polivy. EPAR – Product information, First published 27/01/2020, Last updated 22/03/2023
  • 11 European Medicines Agency, Trodelvy. EPAR – Product information. First published 24/11/2021, Last updated 11/08/2023
  • 12 Food and Drug Administration. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. Drug Approvals and Databases. December 15, 2023
  • 13 Food and Drug Administration. FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer. Drug Approvals and Databases. December 18, 2019
  • 14 Food and Drug Administration. PADCEV® (enfortumab vedotin-ejfv) HIGHLIGHTS OF PRESCRIBING INFORMATION. Revised 12/2023
  • 15 Powles T. et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med 2024; 390: 875-888 DOI: 10.1056/NEJMoa2312117.
    CrossrefPubMedGoogle Scholar
  • 16 Shvartsur A. et al. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 2015; 6: 84-105 DOI: 10.18632/genesandcancer.40.
    CrossrefPubMedGoogle Scholar
  • 17 Younes A. et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363: 1812-1821 DOI: 10.1056/NEJMoa1002965.
    CrossrefPubMedGoogle Scholar